Are vasodilators still indicated in the treatment of severe aortic regurgitation?

Current Cardiology Reports

Volumn 9, Issue 2, 2007, Pages 87-92

  Inano, Jocelyn ^b   Enriquez Sarano, Maurice ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDRALAZINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PLACEBO; PRAZOSIN; QUINAPRIL; VASODILATOR AGENT;

AORTA VALVE REGURGITATION; BLOOD PRESSURE MEASUREMENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG INDICATION; EVIDENCE BASED MEDICINE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HEART OUTPUT; HEART VENTRICLE REMODELING; HUMAN; INDIVIDUALIZATION; LIFE EXPECTANCY; LONG TERM CARE; META ANALYSIS; OUTCOMES RESEARCH; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC VASCULAR RESISTANCE;

AORTIC VALVE INSUFFICIENCY; BLOOD FLOW VELOCITY; DIASTOLE; HUMANS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34247880485     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938333     Document Type: Review

References (41)

1. Enriquez-Sarano M, Tajik AJ: Clinical practice. Aortic regurgitation. N Engl J Med 2004, 351:1539-1546.
2. Dujardin KS, Enriquez-Sarano M, Schaff HV, et al.: Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 1999, 99:1851-1857.
3. Bonow RO, Carabello BA, Chatterjee K, et al.: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): dDeveloped in collaboration with the Society of Cardiovascular Anesthesiologists. Circulation 2006, 114:e84-e231.
4. Iung B, Gohlke-Barwolf C, Tornos P, et al.: Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 2002, 23:1253-1266.
5. Bonow RO, Lakatos E, Maron BJ, Epstein SE: Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991, 84:1625-1635.
6. Tribouilloy CM, Enriquez-Sarano M, Fett SL, et al.: Application of the proximal flow convergence method to calculate the effective regurgitant orifice area in aortic regurgitation. J Am Coll Cardiol 1998, 32:1032-1039.
7. Zoghbi WA, Enriquez-Sarano M, Foster E, et al.: Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003, 16:777-802.
8. Reimold SC, Orav EJ, Come PC, et al.: Progressive enlargement of the regurgitant orifice in patients with chronic aortic regurgitation. J Am Soc Echocardiogr 1998, 11:259-265.
9. Borow KM, Marcus RH: Aortic regurgitation: the need for an integrated physiologic approach. J Am Coll Cardiol 1991, 17:898-900.
10. Chaliki HP, Mohty D, Avierinos J-F, et al.: Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 2002, 106:2687-2693.
11. Wisenbaugh T, Spann JF, Carabello BA: Differences in myocardial performance and load between patients with similar amounts of chronic aortic versus chronic mitral regurgitation. J Am Coll Cardiol 1984, 3:916-23.
12. Ross J Jr: Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol 1985, 5:811-826.
13. Bonow RO, Dodd JT, Maron BJ, et al.: Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. Circulation 1988, 78:1108-1120.
14. Bonow RO, Rosing DR, Maron BJ: Reversal of left ventricular dysfunction after aortic valve replacement for chronic aortic regurgitation: influence of duration of preoperative left ventricular dysfunction. Circulation 1984, 70:570-579.
15. Tarasoutchi F, Grinberg M, Spina GS, et al.: Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology. J Am Coll Cardiol 2003, 41:1316-1324.
16. Roman MJ, Klein L, Devereux RB, et al.: Reversal of left ventricular dilatation, hypertrophy, and dysfunction by valve replacement in aortic regurgitation. Am Heart J 1989, 118:553-563.
17. Bolen JL, Alderman EL: Hemodynamic consequences of afterload reduction in patients with chronic aortic regurgitation. Circulation 1976, 53:879-883.
18. Miller RR, Vismara LA, DeMaria AN: Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume. Am J Cardiol 1976, 38:564-567.
19. Sasayama S, Ohyagi A, Lee JD: Effect of the vasodilator therapy in regurgitant valvular disease. Jpn Circ J 1982, 46:433-441.
20. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH: Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency. Circulation 1981, 63:263-268.
21. Greenberg BH, DeMots H, Murphy E, Rahimtoola S: Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency. Circulation 1980, 62:49-55.
22. Fioretti P, Benussi B, Scardi S: Afterload reduction with nifedipine in aortic insufficiency. Am J Cardiol 1982, 49:1728-1732.
23. Greenberg B, Massie B, Bristow JD, et al.: Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation 1988, 78:92-103.
24. Lin M, Chiang H-T, Lin S-L, et al.: Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol 1994, 24:1046-1053.
25. Schon HR, Dorn R, Barthel P, Schomig A: Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis 1994, 3:500-509.
26. Mori Y, Nakazawa M, Tomimatsu H, Momma K: Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J Am Coll Cardiol 2000, 36:270-275.
27. Banaszewski M, Rydlewska-Sadowska W, Rubkiewicz S: Captopril or nifedipine? Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation. J Heart Valve Dis 1998, 7:488-499.
28. Scognamiglio R, Rahimtoola SH, Fasoli G, et al.: Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994, 331:689-694.
29. Evangelista A, Tornos P, Sambola A, et al.: Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005, 353:1342-1349.
30. Scognamiglio R, Negut C, Palisi M, et al.: Long-term survival and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. J Am Coll Cardiol 2005, 45:1025-1030.
31. Hockings BET, Cope GD, Clarke GM, Taylor RR: Comparison of vasodilator drug prazosin with digoxin in aortic regurgitation. Br Heart J 1980, 43:550-555.
32. Jebavy P, Koudelkova E, Hanzlova M: Unloading effects of prazosin in patients with chronic aortic regurgitation. Am Heart J 1983, 105:567-574.
33. Reske SN, Heck I, Kropp J: Captopril mediated decrease of aortic regurgitation. Br Heart J 1985, 54:415-419.
34. Klepzig H Jr, Mildenberger D, Baum R: Therapeutic effect of captopril in chronic aortic regurgitation. Zeitschrift fur Kardiologie 1986, 75:283-290.
35. Rothlisberger C, Sareli P, Wisenbaugh T: Comparison of single-dose nifedipine and captopril for chronic severe aortic regurgitation. Am J Cardiol 1993, 72:799-804.
36. Shen WF, Roubin GS, Hirasawa K: Noninvasive assessment of acute effects of nifedipine on rest and exercise hemodynamics and cardiac function in patients with aortic regurgitation. J Am Coll Cardiol 1984, 4:902-907.
37. Castini D, Gentile F, Siffredi M, et al.: Does aortic regurgitation affect transmitral flow? An echo-Doppler study. Acta Cardiologica 1993, 48:345-353.
38. Søndergaard L, Aldershvile J, Hildebrandt P, et al.: Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. Am Heart J 2000, 139:667-674.
39. Kleaveland JP, Reichek N, McCarthy DM: Effects of six-month afterload reduction therapy with hydralazine in chronic aortic regurgitation. Am J Cardiol 1986, 57:1109-1116.
40. Wisenbaugh T, Sinovich V, Dullabh A, Sareli P: Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis 1994, 3:197-204.
41. Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S: Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation. J Am Coll Cardiol 1990, 16:424-429.